Back to results
US 2023/0142697 A1Published application
Glycan-Interacting Compounds and Methods of Use
AssigneeSeagen Inc.
InventorsDavid A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
Claims2
An antibody comprising:
- a heavy chain variable domain (VH) comprising an amino acid sequence with at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 66, 64, 65, 67, and 68;
- and
- a light chain variable domain (VL) comprising an amino acid sequence with at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 71, 69, 70, and 72.
2 more elements
2-50. (canceled)
Dependencies are inferred from the claim text.